<dl><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>1</dt><dd id="tr1"><p>{{'LOAD_TRANSACTION'|translate}}</p><ul><li>A file should not be loaded if it is the first REP transaction for this dossier.</li><li>When continuing with a working copy, the format of the file to load should be .hcsc.</li><li>When viewing/updating a final XML file, the format of the file to load should be .xml.</li></ul><p class="fn-rtn"><a href="#tr1_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>1 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>2</dt><dd id="tr2"><p>{{'SECTION_IS_NOT_VISIBLE'|translate}} {{::'RESET'|translate}}</p><p>To enable the "generate final XML" button, select the "reset" button to clear transaction specific fields.<br><br>Company ID must be 5 digits, add leading zero when required.</p><p class="fn-rtn"><a href="#tr2_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>2 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>3</dt><dd id="tr3"><p>{{::'DOSSIER_TYPE'|translate}}</p><ul><li>Biologic dossier applies to all biologic products and radiopharmaceuticals</li><li>Pharmaceutical dossier applies to all pharmaceutical products, non-prescription products, disinfectants</li><li>Veterinary dossier applies to all veterinary products</li><li>Clinical Trial dossier applies to all regulatory activities pursuant to Part C, Division 5 of the Food and Drug Regulations.</li></ul><p class="fn-rtn"><a href="#tr3_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>3 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>4</dt><dd id="tr4"><P>{{::"COMPANY_ID" |translate}}</P><p>The “Company ID” must be obtained from the final company XML file, issued by Health Canada.</p><p>Company ID must be 5 digits, add leading zero when required.</p><p class="fn-rtn"><a href="#tr4_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>4 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>5</dt><dd id="tr5"><P>{{::"DOSSIER_ID" |translate}}</P><p>The “Dossier ID” can be obtained from Health Canada issued document. The format of a Dossier ID is a letter followed by six digits. (e.g. HC6-024-x######).</p><p class="fn-rtn"><a href="#tr5_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>5 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>6</dt><dd id="tr6"><p>{{::"PROD_NAME" |translate}}</p><p>The product name (also known as the brand name or proprietary name) is the name assigned by the manufacturer or sponsor to the dossier (product), and under which the product is to be sold and advertised. The product name is also the name used to identify the product in all submission correspondence, Product Label(s) and Product Monograph/Package Insert, if applicable. If the product name has not yet been determined, the following may be used: “TBD” (short for To Be Determined), the proper or common name of the drug, or the research code.<br><br>The product name input in this field will only be reviewed with the initial transaction of a dossier (sequence 0000). For all subsequence transactions, any changes to the product name should be captured and will be reviewed using the product information template. Product name changes on this template will not be reviewed.</p><p class="fn-rtn"><a href="#tr6_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>6 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>7</dt><dd id="tr7"><p>{{'SECTION_IS_NOT_VISIBLE'|translate}} {{::"PROD_PROTOCOL" |translate}}</p><div class=""><p>The protocol number should remain the same for the duration of the trial. It is acceptable to indicate the version or amendment number of the protocol submitted at the time of application; however, the original protocol number must always be indicated.</p></div><p class="fn-rtn"><a href="#tr7_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>7 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>8</dt><dd id="tr8"><p>{{'SECTION_IS_NOT_VISIBLE'|translate}} {{::"IS_ADMIN_SUBMISSION" |translate}}</p><div class=""><p>Refer to the <a target="_blank" href="https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/guidance-administrative-processing-human-disinfectant-drugs.html">Guidance Administrative Processing of Submissions and Applications: Human or Disinfectant Drugs</a></p></div><p class="fn-rtn"><a href="#tr8_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>8 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>9</dt><dd id="tr9"><p>{{::"CONTROL_NUM" |translate}}</p><ul><li>Enter the 6 digit control number associated with this regulatory activity (if known).</li><li>Enter “000000” for regulatory transactions that Do Not require a control number (e.g. Level III - Post-NOC Changes, UDRA – DIN cancellations, UDRA - Notification Interruption of sale, UDRA - eCTD Dossier Clean-up).</li><li>Enter “000000” for the first transaction of a NEW regulatory activity, where a control number has not yet been assigned.</li><li>Enter the pre-assigned control number for the first transaction of a new regulatory activity that was communicated by Health Canada (e.g. via an Advisement Letter).</li><li>Drug Notification Form(s) (DNF) should be filed under the same control number it has been issued for the product(s) that are now being sold on the market.</li></ul><p class="fn-rtn"><a href="#tr9_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>9 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>10</dt><dd id="tr10"><p>{{::'ACTIVITY_LEAD' |translate}}</p><ul><li>Pharmaceutical: Includes all regulatory activities and transactions for pharmaceutical under the Therapeutic Products Directorate (TPD) mandate.</li><li>Biological: Includes all regulatory activities and transactions under the Biologics and Genetic Therapies Directorate (BGTD) mandate (biologics/radiopharmaceutical).</li><li>Post-Market Vigilance: Includes all regulatory activities and transactions under the Marketed Health Products Directorate (MHPD) mandate.</li><li>Consumer Health Products: Includes all regulatory activities and transactions for non-prescription pharmaceuticals under the Natural and Non-Prescription Health Products Directorate (NNHPD) mandate.</li></ul><p class="fn-rtn"><a href="#tr10_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>10 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>11</dt><dd id="tr11"><p>{{'SECTION_IS_NOT_VISIBLE'|translate}} {{::'YEAR_CHANGE' |translate}}</p><p>For example:<br>2018, 15, 18, 23<br>June 2017 to May 2018, 14, 16, 27<br>2016, 2017, 2018, 5, 8, 17</p><p class="fn-rtn"><a href="#tr11_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>11 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>12</dt><dd id="tr12"><p>{{'SECTION_IS_NOT_VISIBLE'|translate}} {{::'BRIEF_DESC_CHANGE' |translate}}</p><p>Reference the applicable appendix sections of the Post-Notice of Compliance (NOC) Changes Guidance Documents and identify the changes.<br>i.e. Quality Document- 3.2.S Drug Substance #1, 2d, 9b, 17,<br>i.e. Quality Document - 3.2.S Drug Substance (Kits/radiopharmaceuticals containing drug substance of chemical origin) - #3, 9, 10c<br>i.e. Safety and Efficacy Document - Supplements - a, d.</p><p class="fn-rtn"><a href="#tr12_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>12 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>13</dt><dd id="tr13"><p>{{'SECTION_IS_NOT_VISIBLE'|translate}} {{::'SOLICITED_RQ' |translate}}</p><p>If the name of the requester is unknown, enter the generic email the request was sent from.</p><p class="fn-rtn"><a href="#tr13_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>13 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>14</dt><dd id="tr14"><p>{{'SECTION_IS_NOT_VISIBLE'|translate}} {{::'REGULATORY_FEES' |translate}}</p><p>For more information related to fees, refer to the <a target="_blank" href="https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/fees/fees-review-drug-submissions-applications.html">Guidance Document - Fees for the Review of Drug Submissions and Applications</a></p><p class="fn-rtn"><a href="#tr14_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>14 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>15</dt><dd id="tr15"><p>{{'SECTION_IS_NOT_VISIBLE'|translate}} {{::"DEFER_FEES"|translate}}</p><p>If a sponsor has not completed its first full fiscal year on the day that the drug submission, supplement or application is filed, the sponsor is eligible for a two-year deferral of payment from the date of filing. In order to qualify for the deferral period, a statement signed by the individual responsible for the sponsor’s financial affairs specifying the commencement date of the fiscal year must be submitted with the submission, supplement or application. At the end of the two-year period, the sponsor must pay all of the applicable fees.</p><p class="fn-rtn"><a href="#tr15_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>15 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>16</dt><dd id="tr16"><p>{{'SECTION_IS_NOT_VISIBLE'|translate}} {{::'FEE_REMISSION'|translate}}</p><ul><li>When applying for a fee remission, the necessary documentation and the remission processing fee of $590 must accompany the submission, supplement or application. Failing to do so will result in the rejection of the fee remission application.</li><li>In order to be eligible for a remission, the full fee must be more than 10% of the anticipated gross revenue from sales of the product in Canada during the fee verification period of three years. For further information on fee remissions, please refer to the Guidance Document - Fees for the Review of Drug Submissions and Applications.</li><li>The remission processing fee must be included with the drug submission, supplement or application upon filing. Remission requests will not be accepted retroactively. This fee is for the assessment of the information submitted with the application for remission of fees and the audited sales records, and is not considered part of the submission review fee. This fee will not be deducted from the fees payable for the submission review. The remission processing fee can be found in the Submission / Application Fee Form.</li></ul><p class="fn-rtn"><a href="#tr16_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>16 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>17</dt><dd id="tr17"><p>{{::'REG_CONTACT_THIS' |translate}}</p><ul><li>Information provided here pertains to <b>the contact specific to the subject regulatory activity,</b> i.e., the person/company to whom Health Canada should direct correspondence about the subject regulatory activity.</li><li>Please note that it is up to the discretion of Health Canada to decide the method of correspondence.</li><li>If you are adding a record to previously submitted final regulatory transaction xml, these fields will be prepopulated with the information of the previous transaction (sequence number).</li><li>Sponsors should update this information if required; otherwise confirm that the information is still valid.</li><li>Enter the name of the company to which the regulatory activity contact belongs. If the contact does not belong to a company, enter the name of the contact.</li></ul><p class="fn-rtn"><a href="#tr17_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>17 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>18</dt><dd id="tr18"><p>{{::"COMPANY_NOABBREV" |translate}}</p><p>If the company differs from the sponsor, a letter of authorization signed by the manufacturer/sponsor must be provided in section 1.2.6 of the regulatory transaction.</p><p class="fn-rtn"><a href="#tr18_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>18 <span class="wb-inv">referrer</span></a></p></dd><dt><span class="wb-inv">{{::'INSTRUCTION'|translate}} </span>19</dt><dd id="tr19"><p>{{::'GENERATE_FINAL'|translate}}</p><ul><li>A final regulatory transaction XML file must be included in section 1.2.1 for each of your REP transactions.</li><li>Refer to the REP guidance document for detailed information.</li><li>To enable the "generate final XML" button, select the "reset" button to clear transaction specific fields.</li></ul><p class="fn-rtn"><a href="#tr19_ref"><span class="wb-inv">{{::'RETURN_INSTRUCTION'|translate}}</span>19 <span class="wb-inv">referrer</span></a></p></dd></dl>